SCHEMBL2934775

SCHEMBL2934775

CC(C)c1cccc(OC2CN(C(=O)OC(C)(C)C)CC2CN(Cc2ccccc2)c2ccc(Cl)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
REN P00797 2/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
S1PR3 Q99500 1/20 0.36
BACE1 P56817 3/20 0.36
KCNK3 O14649 2/20 0.35
KCNK9 Q9NPC2 2/20 0.35
USP30 Q70CQ3 1/20 0.35
CACNB4 O00305 1/20 0.34
CACNA1A O00555 1/20 0.34
CACNA1G O43497 1/20 0.34
CACNG3 O60359 1/20 0.34
CACNA1F O60840 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNB3 P54284 1/20 0.34
CACNA2D1 P54289 1/20 0.34
CACNG7 P62955 1/20 0.34
CACNA1B Q00975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934776 1.00 MEN1 (0.39) MEN1KMT2ARENJAK2JAK1
SCHEMBL2936292 0.90 MEN1 (0.41) MEN1KMT2AS1PR3BACE1KCNK3
SCHEMBL2936293 0.90 MEN1 (0.41) MEN1KMT2AS1PR3BACE1KCNK3
SCHEMBL2929190 0.87 REN (0.43) MEN1KMT2ARENJAK2JAK1
SCHEMBL2929193 0.87 REN (0.43) MEN1KMT2ARENJAK2JAK1
SCHEMBL2930921 0.86 TACR1 (0.41) MEN1KMT2ARENJAK2JAK1
SCHEMBL2930919 0.86 TACR1 (0.41) MEN1KMT2ARENJAK2JAK1
SCHEMBL2937603 0.82 MEN1 (0.46) MEN1KMT2ARENJAK2JAK1
SCHEMBL2937604 0.82 MEN1 (0.46) MEN1KMT2ARENJAK2JAK1
SCHEMBL2937679 0.81 MEN1 (0.48) MEN1KMT2ARENJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD MEN1 1437/4885KMT2A 3722/4885REN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.